BioSpace News Archive

Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced they will be presenting new scientific data at the American College of Rheumatology’s (ACR/ARHP) Annual Meeting being held November 9-12, 2019 in Atlanta, GA.

DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the AMA has issued a Proprietary Laboratory Analyses (PLA) Common Procedural Terminology (CPT®) Code for the DermTech Pigmented Lesion Assay.

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company’s third quarter 2019 financial results will be released after market close on Monday, November 4, 2019.

Avenue Therapeutics, Inc., a company focused on the development of intravenous tramadol for the U.S. market, announced that its Phase 1 data on intravenous tramadol has been published in the peer-reviewed journal Clinical Pharmacology in Drug Development.

Agreement adds 350 premium tumor PDX models to world’s largest PDX collection

Phase II randomized trial led by investigators at Fox Chase Cancer Center will look at chemotherapy combinations for people with stage IV non-squamous non-small cell lung cancer with EGFR mutation or who never smoked

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Tuesday, November 12, 2019

Arena Pharmaceuticals, Inc. announced that the first subject has been dosed in the Phase 2 ADVISE trial evaluating etrasimod, an investigational next-generation, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, for the potential treatment of moderate-to-severe atopic dermatitis (AD).